VERRICA PHARMACEUTICALS INC (VRCA)
US92511W1080 - Common Stock
VERRICA PHARMACEUTICALS INC
NASDAQ:VRCA (9/16/2024, 8:00:02 PM)
After market: 1.99 +0.1 (+5.29%)1.89
-0.08 (-4.06%)
Company Profile
Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. The company is headquartered in West Chester, Pennsylvania and currently employs 100 full-time employees. The company went IPO on 2018-06-15. The firm is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.
Company Info
VERRICA PHARMACEUTICALS INC
10 N High St Ste 200
West Chester PENNSYLVANIA 19380
P: 14844533300
CEO: Ted White
Employees: 100
Website: https://verrica.com/
VRCA News
3 days ago - Kahn Swick & Foti, LLCVERRICA PHARMACEUTICALS INVESTIGATION CONTINUED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA13 days ago - Verrica Pharmaceuticals Inc.Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York13 days ago - Verrica Pharmaceuticals Inc.Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New YorkWEST CHESTER, Pa., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology...
a month ago - InvestorPlaceVRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024VRCA stock results show that Verrica Pharmaceuticals beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
a month ago - Yahoo FinanceWhy Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday?On Wednesday, dermatology drug developer Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) released preliminary results from Part 2 of its Phase 2 trial of VP-315 for basal cell carcinoma. The Phase 2 trial is a 2-part, open-label, multicenter, dose-escalation, proof-of-concept study with a safety run-in designed to assess the safety and tolerability, pharmacokinetics, and efficacy of VP-315 when administered intratumorally to adults with biopsy-proven basal cell carcinoma. The study enrolled 92 adult
a month ago - Verrica Pharmaceuticals Inc.Verrica Pharmaceuticals Reports Second Quarter 2024 Financial ResultsVRCA Twits
Here you can normally see the latest stock twits on VRCA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits:
